Despite a premium valuation, AMD is positioning itself as a key challenger in the AI chip race, betting big on integrated data center systems to capture surging demand.
DoorDash is accelerating its expansion beyond food delivery with a nationwide partnership to deliver Hibbett's athletic gear and the appointment of a robotics and AI veteran to its board, underscoring its ambition to become a broader commerce platform.
Tower Semiconductor (TSEM) has captured market attention with record revenue guidance and a major $650 million capacity expansion targeting silicon photonics and SiGe technologies. While shares have surged over 58% in 90 days, analysts are now debating whether the stock's premium valuation fully prices in future growth in AI, 5G, and data center markets.
Intuitive Machines (LUNR) is set to acquire Lanteris Space Systems in an $800 million deal, expanding its capabilities into vertically integrated space infrastructure. Concurrently, NASA has selected the company to provide critical tracking support for the upcoming Artemis II crewed lunar mission, signaling growing trust in its technical prowess.
After a challenging year, Pool Corp's shares have shown a notable uptick over the past month, reigniting the debate over its valuation. With a significant gap between its current price and analyst targets, investors are weighing short-term momentum against longer-term headwinds in the housing and outdoor living sectors.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
With hyperscalers projected to pour $500 billion into AI infrastructure by 2026, investors are looking beyond headline chipmakers to the essential, yet often overlooked, backbone providers of the AI revolution.
Once crypto miners, IREN and Applied Digital have pivoted to AI infrastructure, delivering staggering returns. But as valuations soar, investors face a critical choice between predictable cash flow and high-growth optionality.
Once the undisputed leader in connected fitness, Peloton Interactive is navigating a critical business reset. Faced with declining revenue, subscriber churn, and a shifting market, the company is trading rapid expansion for a strategy focused on cost control and stabilization. The core question for investors is whether its brand and ecosystem can sustain a profitable future.
Cisco Systems has inked a major 15-year virtual power purchase agreement for solar energy in Poland, a move that extends its environmental commitments into one of Europe's more fossil-fuel-dependent grids and underscores its long-term capital allocation strategy beyond core tech.
AMD and GIGABYTE have significantly expanded their partnership to co-develop a new generation of AI-accelerated gaming laptops, motherboards, and monitors. This strategic move aims to bring powerful, on-device AI capabilities directly to consumers, potentially reshaping competitive dynamics in the PC gaming hardware market.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Tesla is pivoting its core strategy, phasing out legacy Model S and X production to mass-manufacture Optimus humanoid robots and deepening its commitment to artificial intelligence with a major investment in Elon Musk's xAI. This strategic realignment signals a future where the company's identity may evolve from electric vehicle pioneer to a broader AI and robotics powerhouse.
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
